Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)

Previously, Teva was established as the European commercialisation partner of FYB201, Formycon’s biosimilar to ranibizumab (Lucentis).

Read the full article here

Source: www.ophthalmologytimes.com

Categories: Ophthalmology, General Medicine News

Tweets with this article

Ophthalmology Times

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., announced it would partner with Klinge Biopharma GmbH and Formycon AG in commercializing FYB203, Formycon’s biosimilar candidate to aflibercept https://t.co/0RFlJAlFLR

Eyebright Medical receives Class III Certificate from National Medical Products Administration in China for its phakic intraocular lens

The Loong Crystal PR IOL is designed for the treatment of myopia in adults ranging from -3.25D to -18.00D.

Ophthalmology Times January 15, 2025

Glaucoma Financial Assistance Information – Prevent Blindness

A directory of companies and organizations that provide financial assistance to glaucoma patients to help them afford medications and treatment.

Glaucoma Physician January 15, 2025

Bausch + Lomb acquires Whitecap Biosciences

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

Ophthalmology Times January 15, 2025

Q&A: Pantheon Vision developing alternative to donor tissue for corneal transplants

Despite a worldwide need for more corneal transplant tissue, few options exist beyond human donors.According to a study published in JAMA Ophthalmology, just one cornea…

Ocular Surgery News January 14, 2025

¿Qué es la enfermedad ocular tiroidea (EOT) o enfermedad de Graves?

La enfermedad ocular tiroidea (EOT) o enfermedad de Graves se produce cuando el sistema inmune ataca los músculos y tejidos que rodean los ojos.

NEI January 14, 2025

The Opportunity in Canaloplasty

In the first of a three-part series, William F. Wiley, MD, discusses the evolution of canaloplasty and its role in his cataract practice.

Cataract & Refractive Surgery Today January 14, 2025

Comparison of the Visual Outcomes and Optical Quality of Small Incision Lenticule Extraction and Toric Implantable Collamer Lens Implantation to Correct High Astigmatism | Journal of Refractive Surgery

Purpose To compare 6-month visual outcomes and optical quality after small incision lenticule extraction (SMILE) and toric Implantable Collamer Lens (ICL) (STAAR Surgical Company) implantation…

JRSJournal January 14, 2025

Related Articles